americanpharmaceuticalreviewJune 23, 2021
Tag: Avacta , Calibre , AffiDX
Avacta Group plc announced that it has entered into a non-exclusive distribution agreement with Calibre Scientific Inc. for Avacta’s AffiDX SARS-CoV-2 antigen lateral flow test for use in the UK and European Economic Area (EEA).
Calibre is a diversified global provider of life science products to the diagnostics, healthcare, research, industrial, and biopharmaceutical communities. With headquarters in Los Angeles, California, Calibre has a global reach extending to over 100 countries across a wide array of verticals and geographies.
The non-exclusive distribution agreement for Avacta’s AffiDX SARS-CoV-2 antigen lateral flow test for professional use covers the UK and EEA. The test will be listed on Calibre’s website and available to be purchased by professional users.
Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: “We are delighted that we have put in place this distribution agreement for the AffiDX SARS-CoV-2 antigen lateral flow test for professional use with Calibre.” He continued, “Lateral flow tests have a crucial role to play in helping societies and the global economy return to normal and Avacta’s AffiDX antigen test, developed in the UK and based on UK technology is well placed to play a significant role in this process. I look forward to updating the market on progress over the coming months.”
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: